Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2015

01-12-2015 | Research Article

Single nucleotide polymorphisms (SNPs) of hOGG1 and XRCC1 DNA repair genes and the risk of ovarian cancer in Polish women

Authors: Magdalena M. Michalska, Dariusz Samulak, Hanna Romanowicz, Jan Bieńkiewicz, Maciej Sobkowski, Krzysztof Ciesielski, Beata Smolarz

Published in: Tumor Biology | Issue 12/2015

Login to get access

Abstract

The aim of this study was to determine single nucleotide polymorphisms in hOGG1 (Ser326Cys (rs13181)) and XRCC1 (Arg194Trp (rs1799782)) genes, respectively, and to identify the correlation between them and the overall risk, grading and staging of ovarian cancer in Polish women. Our study comprised 720 patients diagnosed with ovarian cancer and 720 healthy controls. The genotype analysis of hOGG1 and XRCC1 polymorphisms was performed using polymerase chain reaction (PCR)-based restriction fragment length polymorphism (PCR-RFLP). Odds ratios (OR) and 95 % confidence intervals (CI) for each genotype and allele were calculated. Results revealed an association between hOGG1 Ser326Cys polymorphism and the incidence of ovarian cancer. Variant Cys allele of hOGG1 increased the overall cancer risk (OR 2.89; 95 % CI 2.47–3.38; p < .0001). Moreover, ovarian cancer grading remained in a relationship with both analysed polymorphisms; G1 tumours presented increased frequencies of hOGG1 Cys/Cys homozygotes (OR 18.33; 95 % CI 9.38–35.81; p < .0001) and XRCC1 Trp/Trp homozygotes (OR 20.50; 95 % CI 10.17–41.32; p < .0001). Furthermore, G1 ovarian cancers displayed an overrepresentation of Cys and Trp allele. In conclusion, hOGG1 Ser326Cys and XRCC1 Arg194Trp polymorphisms may be regarded as risk factors of ovarian cancer.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
Abdulrahman Jr GO, Rahman GA. Epidemiology of breast cancer in Europe and Africa. J Cancer Epidemiol. 2012;2012:915610.CrossRefPubMed
3.
Limp-Foster M, Kelley MR. DNA repair and gene therapy: implications for translational uses. Environ Mol Mutagen. 2000;35:71–81.CrossRefPubMed
4.
Dietlein F, Thelen L, Reinhardt HC. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet. 2014;30:326–39.CrossRefPubMed
5.
Marin JJ, Briz O, Monte MJ, Blazquez AG, Macias RI. Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs. Curr Cancer Drug Targets. 2012;12:402–38.CrossRefPubMed
6.
Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect. 2003;111:1843–50.CrossRefPubMedPubMedCentral
7.
Wilson DM, Bohr VA. The mechanics of base excision repair, and its relationship to aging and disease. DNA Repair (Amst). 2007;6:544–59.CrossRef
8.
Almeida KH, Sobol RW. A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA Repair (Amst). 2007;6:695–711.CrossRef
9.
10.
Yu Z, Chen J, Ford BN, Brackley ME, Glickman BW. Human DNA repair systems: an overview. Environ Mol Mutagen. 1999;33:3–20.CrossRefPubMed
11.
Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 2003;17:1195–214.CrossRefPubMed
12.
13.
Patel AV, Calle EE, Pavluck AL, Feigelson HS, Thun MJ, Rodriguez C. A prospective study of XRCC1 (X-ray crosscomplementing group 1) polymorphisms and breast cancer risk. Breast Cancer Res. 2005;7:1168–73.CrossRef
14.
Kohno T, Kunitoh H, Toyama K, Yamamoto S, Kuchiba A, Saito D, et al. Association of the OGG1-Ser326Cys polymorphism with lung adenocarcinoma risk. Cancer Sci. 2006;97:724–8.CrossRefPubMed
15.
Poplawski T, Arabski M, Kozirowska D, Blasinska-Morawiec M, Morawiec Z, Morawiec-Bajda A, et al. DNA damage and repair in gastric cancer—a correlation with the hOGG1 and RAD51 genes polymorphisms. Mutat Res. 2006;601:83–91.CrossRefPubMed
16.
De Ruyck K, Szaumkessel M, De Rudder I, Dehoorne A, Vral A, Claes K, et al. Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutat Res. 2007;631:101–10.CrossRefPubMed
17.
Pachouri SS, Sobti RC, Kaur P, Singh J. Contrasting impact of DNA repair gene XRCC1 polymorphisms Arg399Gln and Arg194Trp on the risk of lung cancer in the north-Indian population. DNA Cell Biol. 2007;26:186–91.CrossRefPubMed
18.
Yin J, Vogel U, Ma Y, Qi R, Sun Z, Wang H. The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population. Lung Cancer. 2007;56:153–60.CrossRefPubMed
19.
Hatt L, Loft S, Risom L, Møller P, Sørensen M, Raaschou-Nielsen O, et al. OGG1 expression and OGG1 Ser326Cys polymorphism and risk of lung cancer in a prospective study. Mutat Res. 2008;639:45–54.CrossRefPubMed
20.
Ming-Shiean H, Yu JC, Wang HW, Chen ST, Hsiung CN, Ding SL, et al. Synergistic effects of polymorphisms in DNA repair genes and endogenous estrogen exposure on female breast cancer risk. Ann Surg Oncol. 2010;17:760–71.CrossRefPubMed
21.
Bewick MA, Lafrenie RM, Conlon MS. Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer. J Cancer Res Clin Oncol. 2011;137:543–50.CrossRefPubMed
22.
Zhu S, Zhang H, Tang Y, Wang J. Polymorphisms in XPD and hOGG1 and prostate cancer risk: a meta-analysis. Urol Int. 2012;89:233–40.CrossRefPubMed
23.
Xue X, Yin Z, Lu Y, Zhang H, Yan Y, Zhao Y, et al. The joint effect of hOGG1, APE1, and ADPRT polymorphisms and cooking oil fumes on the risk of lung adenocarcinoma in Chinese non-smoking females. PLoS One. 2013;8, e71157.CrossRefPubMedPubMedCentral
24.
Wang W, Dang S, Li Y, Sun M, Jia X, Wang R, et al. hOGG1 Ser326Cys polymorphism and risk of hepatocellular carcinoma among East Asians: a meta-analysis. PLoS One. 2013;8, e60178.CrossRefPubMedPubMedCentral
25.
Mao Y, Xu X, Lin Y, Chen H, Wu J, Hu Z, et al. Quantitative assessment of the associations between XRCC1 polymorphisms and bladder cancer risk. World J Surg Oncol. 2013;11:58.CrossRefPubMedPubMedCentral
26.
Chen X, Liu X, Wang J, Guo W, Sun C, Cai Z, et al. Functional polymorphisms of the hOGG1 gene confer risk to type 2 epithelial ovarian cancer in Chinese. Int J Gynecol Cancer. 2011;21:1407–13.CrossRefPubMed
27.
Jakubowska A, Gronwald J, Menkiszak J, Górski B, Huzarski T, Byrski T, et al. BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Res Treat. 2010;119:201–11.CrossRefPubMed
28.
Siddiqui-Jain A, Bliesath J, Macalino D, Omori M, Huser N, Streiner N, et al. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Mol Cancer Ther. 2012;11:994–1005.CrossRefPubMed
29.
Kang S, Sun HY, Zhou RM, Wang N, Hu P, Li Y. DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy. Asian Pac J Cancer Prev. 2013;14:941–6.CrossRefPubMed
30.
Miao J, Zhang X, Tang QL, Wang XY, Kai L. Prediction value of XRCC 1 gene polymorphism on the survival of ovarian cancer treated by adjuvant chemotherapy. Asian Pac J Cancer Prev. 2012;13:5007–10.CrossRefPubMed
31.
Li K, Li W. Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population. Mol Cell Biochem. 2013;372:27–33.CrossRefPubMed
32.
Cheng CX, Xue M, Li K, Li WS. Predictive value of XRCC1 and XRCC3 gene polymorphisms for risk of ovarian cancer death after chemotherapy. Asian Pac J Cancer Prev. 2012;13:2541–5.CrossRefPubMed
33.
Pecorelli S, Benedet JL, Creasman WT, Shepherd JH. FIGO staging of gynecologic cancer. 1994–1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet. 1999;65:243–9.CrossRefPubMed
34.
35.
36.
Clancy S. DNA damage & repair: mechanisms for maintaining DNA integrity. Nat Educ. 2008;1:103.
37.
Brown TA. Chapter 14. In: Department of Biomolecular Sciences, UMIST, editor. Genomes. 2nd ed. Manchester: Oxford Wiley-Liss; 2002.
38.
Rastogi RP, Richa, Kumar A, Tyagi MB, Sinha RP. Molecular mechanisms of ultraviolet radiation-induced DNA damage and repair. J Nucleic Acids. 2010;2010:592980.CrossRefPubMedPubMedCentral
39.
Frank SA. Genetic predisposition to cancer—insights from population genetics. Nat Rev Genet. 2004;5:764–72.CrossRefPubMed
40.
Abdel-Rahman SZ, El-Zein RA. The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett. 2000;159:63–71.CrossRefPubMed
41.
Wang Y, Spitz MR, Zhu Y, Dong Q, Shete S, Wu X. From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair. 2003;2:901–8.CrossRefPubMed
42.
Vodicka P, Stetina R, Polakova V, Tulupova E, Naccarati A, Vodickova L, et al. Association of DNA repair polymorphisms with DNA repair functional outcomes in healthy human subjects. Carcinogenesis. 2007;28:657–64.CrossRefPubMed
43.
Silva SN, Moita R, Azevedo AP, Gouveia R, Manita I, Pina JE, et al. Menopausal age and XRCC1 gene polymorphisms: role in breast cancer risk. Cancer Detect Prev. 2007;31:303–9.CrossRefPubMed
44.
Tsai CW, Tsai MH, Tsou YA, Shih LC, Tseng HC, Chang WS, et al. The joint effect of smoking and hOGG1 genotype on oral cancer in Taiwan. Anticancer Res. 2012;32:3799–803.PubMed
45.
Ji C, Liu Z, Chen H, Guo H, Liu C. An association between hOGG1 Ser326Cys polymorphism and the risk of bladder cancer in non-smokers: a meta-analysis. BMC Cancer. 2012;12:335.CrossRefPubMedPubMedCentral
46.
Wang W, Wang M, Chen Y, Zhang Z, Wang S, Xu M, et al. The hOGG1 Ser326Cys polymorphism contributes to cancer susceptibility: evidence from 83 case–control studies. Mutagenesis. 2012;27:329–36.CrossRefPubMed
47.
Zhang M, Mo R. Association of hOGG1 Ser326Cys polymorphism with colorectal cancer risk: an updated meta-analysis including 5235 cases and 8438 controls. Tumour Biol. 2014;35:12627–33.CrossRefPubMed
48.
Yin ZB, Hua RX, Li JH, Sun C, Zhu JH, Su X, et al. Smoking and hOGG1 Ser326Cys polymorphism contribute to lung cancer risk: evidence from a meta-analysis. Tumour Biol. 2014;35:1609–18.CrossRefPubMed
49.
Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS, et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol. 2009;113:264–9.CrossRefPubMed
50.
Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 2010;10:54–61.CrossRefPubMed
Metadata
Title
Single nucleotide polymorphisms (SNPs) of hOGG1 and XRCC1 DNA repair genes and the risk of ovarian cancer in Polish women
Authors
Magdalena M. Michalska
Dariusz Samulak
Hanna Romanowicz
Jan Bieńkiewicz
Maciej Sobkowski
Krzysztof Ciesielski
Beata Smolarz
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3707-5

Other articles of this Issue 12/2015

Tumor Biology 12/2015 Go to the issue

Editorial

The association between methylenetetrahydrofolate reductase gene C677T polymorphisms and breast cancer risk in Chinese population

Research Article

Correlation between serum levels of vascular endothelial growth factor-C and sentinel lymph node status in early breast cancer

Research Article

Differentially expressed protein-coding genes and long noncoding RNA in early-stage lung cancer

Research Article

Resveratrol induces AMPK-dependent MDR1 inhibition in colorectal cancer HCT116/L-OHP cells by preventing activation of NF-κB signaling and suppressing cAMP-responsive element transcriptional activity

Research Article

Association between cell cycle gene transcription and tumor size in oral squamous cell carcinoma

Research Article

RETRACTED ARTICLE: MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits